GlassScriptPhysician profile
Fady F Haddad
NPI 1306286372
$4,121.00
in general payments reported to CMS, 2019-2025
26 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.84 · 2021: $99.90 · 2022: $571 · 2023: $1,087 · 2024: $1,290 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,417.20 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $351.30 | 2022-2025 | Ocaliva |
| Pfizer INC. | $283.06 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.88 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $228.55 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $227.97 | 2023-2025 | Entyvio |
| Madrigal Pharmaceuticals | $212.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $185.20 | 2024 | Bylvay, Iqirvo |
| Regeneron Healthcare Solutions, INC. | $143.36 | 2022-2024 | Dupixent |
| Genzyme Corporation | $119.13 | 2023 | |
| Janssen Biotech, INC. | $104.05 | 2022-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $78.10 | 2021-2024 | Dificid |
| Celltrion USA INC. | $72.13 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $71.91 | 2025 | Vowst |
| Braintree Laboratories, INC. | $61.67 | 2020-2024 | Sutab, Suflave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $56.89 | 2021-2024 | Sucraid, Sucraid |
| Mallinckrodt Hospital Products INC. | $47.97 | 2023 | Terlivaz |
| Tela Bio, INC. | $46.69 | 2024 | Ovitex 2s |
| Gilead Sciences, INC. | $38.48 | 2023 | |
| Celgene Corporation | $29.89 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $23.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.61 | 2023 | Cyltezo |
| Medtronic, INC. | $21.04 | 2025 | V-Loc 180 |
| Ardelyx, INC. | $20.32 | 2025 | Ibsrela |
| Novo Nordisk INC | $15.38 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $10.61 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.